The thrombin (IIa) catalyzed cleavage of soluble fibrinogen (Fbg) to form fibrin (Fbn) is the terminal proteolytic event in the coagulation cascade. These soluble Fbn monomers spontaneously polymerize to form an insoluble Fbn network which is stabilized by the factor XIIIa catalyzed crosslinking of lys and glu residues of α and γ chains. This Fbn network is the major protein component of the hemostatic plug.
Plasma fibrinogen is large glycoprotein (Mr=340,000) synthesized in the liver and circulating at a concentration of 2.6 mg/ml. It is a disulfide linked dimer composed of 3 pairs of disulfide linked non-identical polypeptide chains (Aα, Bβ and γ). Notable features of the Aα chain are the N-terminal peptide (fibrinopeptide A (FPA, 1-16)), factor XIIIa crosslinking sites and 2 phosphorylation sites. When synthesized, Fbg is fully phosphorylated, but circulates at only 20-30% phosphorylation. The Bβ chain contains fibrinopeptide B (FPB, 1-14), one of the 3 N-linked carbohydrate moieties (Mr=2500) and an N-terminal pyroglutamic acid. The γ chain contains the other N-linked glycosylation site and a factor XIIIa crosslinking sites. The 2 elongated subunits ((AαBβγ)2) are aligned in an antiparallel manner forming a trinodular arrangement of the six chains. The nodes are formed by disulfide rings between the 3 parallel chains. The central node (n-disulfide knot, E domain) is formed by the N-termini of all six chains held together by 11 disulfide bonds. This region contains the 2 IIa-sensitive sites. The release of FPA by cleavage at R16-G17 generates Fbn I, exposing a polymerization site (17-20) on the Aα chain. These regions bind to complimentary regions on the D domain of Fbn to form protofibrils. Subsequent IIa cleavage of FPB (R14-G15) from the Bβ chain exposes additional polymerization sites and promotes lateral growth of the Fbn network.
Each of the 2 domains between the central node (E domain) and the C-terminal nodes (D domain) is composed of parallel α-helical regions of the Aα, Bβ and γ chains coiled around each other to form a "coiled coil" with polar residues directed outward and nonpolar residues forming a hydrophobic core. In this region, all 3 chains possess a protease (plasmin) sensitive site. The other major plasmin sensitive site is in the hydrophilic preturbance of the α-chain from the C-terminal node. Controlled plasmin degradation at these sites converts Fbg into fragment D and fragment E. The individual fragments are isolated by salt fractionation, gel filtration and ion exchange chromatography. The fragments are supplied lyophilized for storage at 4°C. Highly purified research grade fibrinogen (>95% clottable) is prepared by a combination of conventional and affinity techniques. It is supplied as a frozen solution in ctirate-phosphate for storage at -80°C.
Haemtech Biopharma可以运行多种分析技术，以提供对蛋白质药物产品或物质的生化分析，或帮助进行污染物鉴定。我们的测定，测试和技术菜单包括：应用领域IVIG药物的血栓形成性过程中杂质分析与止血有关的抗药物抗体测试（免疫原性）例如抗凝血因子抗体宿主细胞蛋白质的鉴定，定量和缓解在制品和在制品中药品的稳定性和释放测试与止血相关的重组蛋白的效力和纯度测定血浆蛋白分析蛋白质的结构表征翻译后修饰二硫键映射构象变化凝血测定试剂（例如凝血活酶）的表征定制的凝血产品检测应用药代动力学研究分析鉴定/验证工艺/产品验证蛋白质纯化方法的发展强迫降解研究方法高效液相色谱反相（RPC）大小排除（SEC）离子交换（IEC）疏水相互作用（HIC）金属亲和力（IMAC）蛋白质A（用于IVIG分析）SDS页面减少和不减少一维和二维考马斯亮蓝染色银染荧光染色免疫印迹多重分析定量化凝血测定因子分析（II，V，VII，VIII，IX，X，XI，XII，XIII等）PTPTPT行动计划福尔摩斯测试其他ELISA法各种显色测定因子分析（II，V，VII，VIII，IX，X，XI，XII，XIII等）其他翻译后修饰分析糖基化，硫酸化，磷酸化，羟基化，脱酰胺，乙酰化，氧化，氨基甲酸酯化和γ-羧化凝血酶生成测定对于IVIG和其他抗药物抗体ELISA（ADA）抗原料药抗体抗宿主细胞蛋白的抗体抗污染物或分解产物的抗体鉴定未知质谱N端测序残留水分测定顶空真空测量pH值渗透压折光率总蛋白质配方评估
